Takeda’s FRUZAQLA gains Health Canada approval, offering hope for metastatic colorectal cancer patients
Takeda Canada Inc. has achieved a significant milestone with the Health Canada approval of FRUZAQLA (fruquintinib), a targeted oral therapy for patients with metastatic colorectal ... Read More
Takeda signs licensing deal for Hutchmed’s fruquintinib outside of China
Takeda Pharmaceutical will acquire an exclusive worldwide license, excluding China, of fruquintinib from Hutchmed (China) and its subsidiary Hutchmed to strengthen its oncology portfolio. Under ... Read More